Chimeric antigen receptor T-cell therapy for HIV cure

Area of Science:

• Immunology
• Virology
• Biotechnology

Background:

• Chimeric antigen receptor (CAR)-T cell therapies have advanced significantly for hematologic cancers.
• The success of anti-CD19 CAR-T cells has spurred interest in their application for HIV treatment.

Purpose of the Study:

• To review the historical and recent advancements in the development of anti-HIV CARs.
• To discuss the potential of CAR-T cell therapy in managing HIV infection.

Main Methods:

• Development of CARs targeting HIV glycoproteins (gp120/gp41).
• Utilizing CD4+ extracellular domains or variable heavy/light chain (VH/VL) segments from broadly neutralizing antibodies.
• Engineering T cells for multiplexed specificities, enhanced signaling, and HIV resistance.

Main Results:

• New generations of anti-HIV CARs have been developed since the 1990s.
• Preclinical studies in mouse models have shown promising results for novel anti-HIV CAR-T cells.
• Ongoing research focuses on optimizing CAR design for efficacy and safety.

Conclusions:

• Anti-HIV CAR-T cell therapies are progressing towards clinical evaluation.
• Key challenges include controlling the HIV reservoir and minimizing off-target effects.
• Further research is needed to establish the safety and efficacy of CAR-T cells for HIV treatment.